TSHA · Taysha Gene Therapies Inc
United States · RS rating 22 · As of 2026-11-03
| Price | 4.09 USD |
|---|---|
| 1-day change | +2.2% |
| RS rating (overall / 1M / 3M / 12M) | 22 / 37 / 16 / 38 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 26 / 5 / 15 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -8.3% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +41.4% |
| Market cap (USD) | $1.8B |